Pathogenetic approaches to treatment of cognitive disorders in patients with diabetes mellitus

Solov'eva É.Iu.; Dzhutova E.D.; Knyazeva V.S.

doi:https://doi.org/10.17116/jnevro20161167185-93

Close metadata

Recommended articles:

Oxidative stress in the pathogenesis of chronic headache. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(10):35-40

Vitamin B12 deficiency in the elderly and its associations with geriatric syndromes. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(10):41-47

Cognitive impairment in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):81-90

Comorbidity of depression and dementia: epidemiological, biological and therapeutic aspects. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):113-121

The role of drug Cytoflavin in the correction of dysautonomia in patients with post-COVID syndrome. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):140-146

Resolution of the expert council «Possibilities of neuroprotective therapy in patients with arterial hypertension and cognitive disorders». Russian Journal of Preventive Medicine. 2024;(11):85-93

Alterations in the activity of glutathione-dependent enzymes in erythrocytes of patients with acute pancreatitis of varying severity. Russian Journal of Evidence-Based Gastroenterology. 2024;(4):10-15

The role of quantitative body composition analysis in population in the assessment and monitoring of cardiovascular risk metabolic factors. Russian Journal of Preventive Medicine. 2024;(12):128-134

Restoration of spermatogenesis suppressed by the use of testosterone, antiestrogen therapy in men with type 2 diabetes mellitus. Russian Journal of Human Reproduction. 2024;(6):156-160

Diabetic retinopathy and pregnancy. Russian Annals of Ophthalmology. 2024;(6):145-151

Abstract:

The article presents the currents concepts on the mechanisms of brain lesions and development of cognitive impairment in diabetes mellitus (DM) including DM type 2. Metabolic and vascular mechanisms, oxidative stress, hyperglycemia, glutamate excitotoxicity, insulin insufficiency and brain insulin resistance, general vascular and microcirculatory disturbances, death of cortical neurons, decrease in the newly synthesized acetylcholine, activation of lipid peroxidation are considered. A review of the main domestic and international drugs used in clinical practice for treatment of cognitive impairment in patients with DM is presented.

Keywords:

diabetes mellitus

cognitive disorders

dementia

oxidative stress

emoxypine

succinic acid

choline alfoscerate

hyperglycemia

Authors:

Solov'eva É.Iu.

Kafedra nevrologii FUV GOU VPO RGMU, Moskva

Dzhutova E.D.

Pirogov Russian National Research Medical University, Moscow, Russia

Knyazeva V.S.

Pirogov Russian National Research Medical University, Moscow, Russia

Close metadata

References:

Biessels GJ. Cerebral complications of diabetes: clinical findings and pathogenetic mechanisms. The Netherlands Journal of Medicine. 1999;54:35-45. doi: 10.1016/S0300-2977(98)00134-X
Ryan CM, Geckle MO. Circumscribed cognitive dysfunction in middle-aged adults with type 2 diabetes. Diabetes Care. 2000;23:1486-1493. doi: 10.2337/diacare.23.10.1486.
Strokov IA, Zaharov VV, Strokov KI. Diabeticheskaja jencefalopatija. Nevrologija, nejropsihiatrija, psihosomatika. 2012;4(2):30-40. doi: 10.14412/2074-2711-2012-2506
Shprah VV, Falieva EM, Akulova EM, Sajutina SB, Mihalevich IM. Discirkuljatornaja jencefalopatija u bol'nyh saharnym diabetom. Nevrologicheskij zhurnal. 1998;6:32-34. (In Russ.).
Mattis S. Mental status examination for organic mental syndrome in the elderly patients. In: Bellack L., Karasu TB., eds. Geriatric Psychiatry. New York: Grunea Sratton; 1976;383.
Cox DJ, Kovatchev BP, Gonder-Frederick LA et al. Relationships Between Hyperglycemia and Cognitive Performance Among Adults With Type 1 and Type 2 Diabetes. Diabetes Care. 2005;28(1):71-77. doi: 10.2337/diacare.28.1.71.
Strachan MWJ, Reynolds RM, Frier BM, Mitchell RJ, Price JF. The relationship between type 2 diabetes and dementia. British Medical Bulletin. 2008;88(1):131-146. doi: 10.1093/bmb/ldn042
Mijnhout GS, Scheltens P, Diamant M, Wessels AM, Simsek S, Heine RJ. Diabetic encephalopathy: a concept in need of a definition. Diabetologia. 2006;49(6):1447-1448. doi: 10.1007/s00125-006-0221-8
Bruce DG, Casey GP, Drange V, Clarnette RC, Almeida OP, Foster JK, Davis TME. Cognitive impairment, physical disability and depressive symptoms in older diabetic patients: the Fremantle Cognition in Diabetes Study. Diabetes Research and Clinical Practice. 2003;61(1):59-67. doi: 10.1016/s0168-8227(03)00084-6
Gregg EW, Brown AA. Cognitive and physical disabilities and aging-related complications of diabetes. Cognitive and Physical Disabilities and Aging-Related Complications of Diabetes. Clinical Diabetes. 2003;21(3):113-118. doi: 10.2337/diaclin.21.3.113
Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. The Lancet Neurology. 2006;5(1):64-74. doi: 10.1016/s1474-4422(05)70284-2
Cukerman T, Gerstein HC, Willamson JD. Cognitive decline and dementia in diabetes - systematic overview of prospective observation studies. Diabetologia. 2005;48(12):2460-2469. doi: 10.1007/s00125-005-0023-4
UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317(7160):703-713. doi: 10.1136/bmj.317.7160.703
Wredling R, Levander S, Adamson U, Lins PE. Permanent neuropsychological impairment after recurrent episodes of severe hypoglycaemia in man. Diabetologia. 1990;33(3):152-157. doi: 10.1007/bf00404042
Firsov AA, Mashhenko EA. Kognitivnye narushenija pri saharnom diabete u lic pozhilogo vozrasta. Arhiv vnutrennej mediciny. 2014;4(18):26-31. (In Russ.).
Luchsinger JA, Tang MX, Stern Y, Shea S, Mayeux R. Diabetes mellitus and risk of dementia in a multiethnic cohort . American Journal of Epidemiology. 2001;154(7):635-641. doi: 10.1093/aje/154.7.635
Xu WL, Qiu CX, Wahlin A, Winblad B, Fratiglioni L. Diabetes mellitus and risk of dementia in the Kungsholmen project: A 6-year follow-up study. Neurology. 2004;63(7):1181-1186. doi: 10.1212/01.wnl.0000140291.86406.d1
de la Monte SM, Wands JR. Alzheimer’s disease is type 3 diabetes-evidence reviewed. Journal of Diabetes Science and Technology. 2008;2(6):1101-1113. doi: 10.1177/193229680800200619
Inoguchi T, Li P, Umeda F, Yu HY, Kakimoto M, Imamura M, Nawata H. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes. 2000;49(11):1939-1945. doi: 10.2337/diabetes.49.11.1939.
Esin RG, Hajrulin IH, Esin OR. Sovremennye predstavlenija o mehanizmah kognitivnyh rasstrojstv pri saharnom diabete. Medicinskij al'manah. 2013;1(25):135-138. (In Russ.).
Peila R, Rodriguez BL, Launer LJ. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia Aging Study. Diabetes. 2002;51(4):1256-1262. doi: 10.2337/diabetes.51.4.1256
Messier C. Diabetes, Alzheimer's disease and apolipoprotein genotype. Experimental Gerontology. 2003;38(9):941-946. doi: 10.1016/S0531-5565(03)00153-0
Etgen T, Sauder D, Bichel H, Sander K, Forstl H. Cognitive decline: the relevance of diabetes, hyperlipidaemia and hypertension. The British Journal of Diabetes & Vascular Disease. 2010;10(3):115-122. doi: 10.1177/1474651410368408
Hassing LB, Hofer SM, Nilsson SE, Berg S, Pedersen NL, McClearn G, Johansson B. Comorbid type 2 diabetes mellitus and hypertension exacerbates cognitive decline: evidence from a longitudinal study. Age and Ageing. 2004;33(4):355-361. doi: 10.1093/ageing/afh100
Posner HB, Tang MX, Luchsinger J, Lantigua R, Stern Y, Mayeux R. The relationship of hypertension in the elderly to AD, vascular dementia, and cognitive function. Neurology. 2002;58(8):1175-1181. doi: 10.1212/wnl.58.8.1175
MacKnight C, Rockwood K, Awalt E, McDowell I. Diabetes mellitus and the risk of Alzheimer’s disease and vascular cognitive impairment in the Canadian Study of Health and Aging. Dementia and Geriatric Cognitive Disorders. 2002;14(2):77-83. doi: 10.1159/000064928
Chugunov PA, Semenova IV, Orlov JuJu, Shestakova MV. Saharnyj diabet i kognitivnye narushenija. Saharnyj diabet. 2008;1:61-68. doi: 10.14341/2072-0351-5948 (In Russ.).
McGuire LC, Ford ES, Ajani UA. The impact of cognitive functioning on mortality and the development of functional disability in older adults with diabetes: the second longitudinal study on aging. BMC Geriatrics. 2006;6(1):8. doi: 10.1186/1471-2318-6-8
Kodl CT, Seaquist ER. Cognitive dysfunction and diabetes mellitus. Endocrine Reviews. 2008;29(4):494-511. doi: 10.1210/er.2007-0034
Yamagishi S, Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Current Pharmaceutical Design. 2005;11(18):2279-2299. doi: 10.2174/1381612054367300
Nielson KA, Nolan JH, Berchtold NC, Sandman C, Mulnard RA, Cotman CW. Apolipoprotein-E genotyping of diabetic dementia patients: is diabetes rare in Alzheimer’s disease? Journal of the American Geriatrics Society. 1996;44(8):897-904. doi: 10.1111/j.1532-5415.1996.tb01857.x
Sima AA, Kamiya H, Li ZG. Insulin, C-peptide, hyperglycemia, and central nervous system complications in diabetes. European Journal of Pharmacology. 2004;490(1-3):187-197. doi: 10.1016/j.ejphar.2004.02.056
Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. The Journal of the American medical Associaton. 2002;287(19):2570. doi: 10.1001/jama.287.19.2570
Efimov AS. Diabeticheskie angiopatii. M.: Medicina; 1989: 288. (In Russ.).
Brookes PS, Levonen A-L, Shiva S, Sarti P, Darley-Usmar VM. Mitochondria: regulators of signal transduction by reactive oxygen and nitrogen Free Radical Biology and Medicine. 2002;33(6):755-764. doi: 10.1016/s0891-5849(02)00901-2
Satarkov AA, Fiskum G, Chinopoulos C, Lorenzo BJ, Browne SE, Patel MS, Beal MF. Mitochondrial α-ketoglutarate dehydrogenase complex generates reactive oxygen species. Journal of Neuroscience. 2004;24:7779-7788. doi: 10.1523/jneurosci.1899-04.2004
Boullier A, Bird DA, Chang MK, Dennis EA, Friedman P, Gillotre-Taylor K, Hörkkö S, Palinski W, Quehenberger O, Shaw P, Steinberg D, Terpstra V, Witztum JL. Scavenger receptors, oxidized LDL, and atherosclerosis. Annals of the New York Academy of Sciences. 2001;947:214-222. doi: 10.1111/j.1749-6632.2001.tb03943.x
Kiray M, Bagriyanik HA, Pekcetin C, Ergur BU, Uysal N, Ozyurt D, Buldan Z. Deprenyl and the relationship between its effects on spatial memory, oxidant stress and hippocampal neurons in aged male rats. Physiological Research. 2006;55(2):205-212.
Voronina TA. Meksidol: spektr farmakologicheskih jeffektov. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2012;12:86-90. (In Russ.)
Voronina TA. Antioksidant meksidol. Osnovnye nejropsihotropnye jeffekty i mehanizm dejstvija. Psihofarmakologija i biologicheskaja narkologija. 2001;1(1):2-12. (In Russ.).
Val'dman AV, Voronina TA, Smirnov LD. Vlijanie proizvodnyh 3-oksipiridinov na central'nuju nervnuju sistemu. Bjulleten' jeksperimental'noj biologii i mediciny. 1985;1:60-62. (In Russ.).
Djumaev KM, Voronina TA, Smirnov LD. Antioksidanty v profilaktike i terapii patologij CNS. M.: Izdatel'stvo Instituta biomedicinskoj himii; 1995. (In Russ.).
Voronina TA, Smirnov LD, Gorjajnova II. Mehanizm dejstvija i obosnovanie primenenija preparata meksidol v nevrologii: metodicheskie rekomendacii. M.: Inctitut biohimicheskoj fiziki, NII farmakologii RAMN. 2002. (In Russ.).
Fedin AI, Rumjanceva SA, Mironova OP, Evseev VN. Primenenie antioksidanta «Meksidol» u bol'nyh s ostrym narusheniem mozgovogo krovoobrashhenija: metodicheskie rekomendacii. M.: RGMU; 2002. (In Russ.).
Burlakova EB, Kajrane ChB, Molochkina EM, Hohlov AP. Modifikacija lipidov naruzhnoj membrany mitohondrij pecheni myshej i kineticheskih parametrov membranosvjazannoj monoaminoksidazy in vivo i in vitro. Voprosy medicinskoj himii. 1984;1:66-71. (In Russ.).
Volchegorskij IA, Miroshnichenko IJu, Rassohina LM, Malkin MP, Fajzulin RM, Prjahina KE, Kalugina AV. Antidepressivnoe dejstvie proizvodnyh 3-oksipiridina i jantarnoj kisloty v jeksperimente. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2015;115(2):48-52. doi: 10.17116/jnevro20151152148-5 (In Russ.).
Volchegorskij IA, Mester NV. Vlijanie proizvodnyh 3-oksipiridina na projavlenija depressii i kognitivnye funkcii u bol'nyh saharnym diabetom. Biomedicina. 2006;3:98-100. (In Russ.).
Chashhina EN. Sravnitel'nyj analiz vlijanija proizvodnyh 3-oksipiridina i jantarnoj kisloty na projavlenija distal'noj simmetrichnoj polinejropatii u bol'nyh saharnym diabetom s sindromom diabeticheskoj stopy: Dis. kand. med. nauk. Cheljabinsk; 2005. Ssylka aktivna na 22.03.16. Dostupno po: http://dlib.rsl.ru/loader/view/01002941986?get=pdf (In Russ.).
Tanashjan MM, Lagoda OV, Antonova KV. Hronicheskie cerebrovaskuljarnye zabolevanija na fone metabolicheskoju sindroma: novye podhody k lecheniju. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2012;112(11):21-26. (In Russ.).
Volchegorskij NA, Rassohina LM, Miroshnichenko IJu. Cerebroprotektivnye jeffekty jemoksipina, reamberina i meksidola pri alloksanovom diabete. Bjulleten' jeksperimental'noj biologii i mediciny. 2013;155(1):56-64. doi: 10.1007/s10517-013-2079-3 (In Russ.).
Zamora M, Pardo R, Villena JA. Pharmacological induction of mitochondrial biogenesis as a therapeutic strategy for the treatment of type 2 diabetes. Biochemical Pharmacology. 2015;98(1):16-28. doi: 10.1016/j.bcp.2015.06.032
Klebanov GI, Ljubickij OB, Vasil'eva OV, Klimov JuV, Penzulaeva OB, Tepljashin AS, Tolstyh MP, Promorenko VK, Vladimirov JuA. Antioksidantnye svojstva proizvodnyh 3-oksipiridina: meksidola, jemoksipina i proksipina. Voprosy medicinskoj himii. 2001;47:288-300. (In Russ.).
Duma SN, Ragino JuI. Rol' antioksidantov v korrekcii psihovegetativnyh, astenicheskih i kognitivnyh narushenij. Trudnyj pacient. 2011;9(4):8-15. (In Russ.).
Tayebati SK, Amenta F. Choline-containing phospholipids: relevance to brain functional pathways. Clinical Chemistry and Laboratory Medicine. 2013;51(3). doi: 10.1515/cclm-2012-0559
Scapicchio PL. Revisiting choline alphoscerate profile: a new, perspective, role in dementia? International Journal of Neuroscience. 2013;123(7):444-449. doi: 10.3109/00207454.2013.765870
Ushkalova EA. Ushkalova AV. Farmakoterapija kognitivnyh narushenij razlichnogo geneza: sovremennoe sostojanie i perspektivnye napravlenija. Russkij medicinskij zhurnal. 2014;22:1613-1617. (In Russ.).
Parnetti L, Mignini F, Tomassoni D, Traini E, Amenta F. Cholinergic precursors in the treatment of cognitive impairment of vascular origin: Ineffective approaches or need for re-evaluation? Journal of the Neurological Sciences. 2007;257(1-2):264-269. doi: 10.1016/j.jns.2007.01.043
Sangiorgi GB, Barbagallo M, Giordano M, Meli M, Panzarasa R. α-Glycerophosphocholine in the Mental Recovery of Cerebral Ischemic Attacks. Annals of the New York Academy of Sciences. 1994;717(1):253-269. doi: 10.1111/j.1749-6632.1994.tb12095.x
Kamchatnov PR, Abusueva BA, Evzel'man MA, Esin RG, Kol'jak EV, Novikova LB, Prikazchikov SV, Rjabov AG, Umarova HJa, Bojko A.N. Jeffektivnost' ceretona pri ostrom ishemicheskom insul'te (rezul'taty issledovanija SOLNCE). Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2012;3(2):10-14. (In Russ.).
Levin OS, Batukaeva LA, Anikina MA, Junishhenko NA. Jeffektivnost' i bezopasnost' holina al'foscerata (ceretona) u pacientov s bolezn'ju Parkinsona s kognitivnymi narushenijami. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2009;109(11):42-46. (In Russ.).
Traini E, Bramanti V, Amenta F. Choline alphoscerate (alpha-glyceryl-phosphoryl-choline) an old choline-containing phospholipid with a still interesting profile as cognition enhancing agent. Current Alzheimer Research. 2013;10(10):1070-1079. doi: 10.2174/15672050113106660173
Amenta F, Carotenuto A, Fasanaro AM, Rea R, Traini E. The ASCOMALVA trial: association between the cholinesterase inhibitor donepezil and the cholinergic precursor choline alphoscerate in Alzheimer’s disease with cerebrovascular injury: interim results. Journal of the Neurological Sciences. 2012;322(1-2):96-101. doi: 10.1016/j.jns.2012.07.003
Shmyrev VI, Kryzhanovskij SM. Kombinirovannaja terapija ishemicheskogo insul'ta holina al'fosceratom i jetilmetilgidroksipiridina sukcinatom. Farmateka. 2013;9:79-83. (In Russ.).
Seregin VI. Primenenie gliatilina i meksidola v intensivnoj terapii tjazhelogo ostrogo ishemicheskogo insul'ta. Farmateka. 2006;5. (In Russ.).
Gennis R. Biomembrany: Molekuljarnaja struktura i funkcii. M.: Mir; 1997.
Bazan NG, eds. Neuronal cell signal transduction and second messengers in cerebral ischemia. Stuttgart: Wissenschaftliche Verlagsgesellschaft; 1990.
Siesjö BK. Hypoglycemia, brain metabolism, and brain damage. Diabetes / Metabolism Reviews. 1988;4(2):113-144. doi: 10.1002/dmr.5610040203
Agut J, Font E, Sacristn A, Ortiz JA. Radioactivity incorporation into different cerebral phospholipids after oral administration of 14C methyl CDP-choline. Arzneimittelforschung. 1983;33:1048-1050.
D’Orlando KJ, Sandage BW Jr. Citicoline (CDP-choline): mechanisms of action and effects in ischemic brain injury. Neurological Research. 1995;17:281-284. doi: 10.1046/j.0022-3042.2001.00697.x
Rao AM, Hatcher JF, Dempsey RJ. Does CDP-choline modulate phospholipase activities after transient forebrain ischemia? Brain Research. 2001;893(1-2):268-272. doi:10.1016/s0006-8993(00)03280-7
Adibhatla RM, Hatcher JF. Citicoline decreases phospholipase A2 stimulation and hydroxyl radical generation in transient cerebral ischemia. Journal of Neuroscience Research. 2003;73(3):308-315. doi: 10.1002/jnr.10672.
Zweifler RM. Membrane Stabilizer: Citicoline. Current Medical Research and Opinion. 2002;18(suppl 2):14-17. doi: 10.1185/030079902125000679
Barancevich ER, Posohina OV. Podhody k terapii nevrologicheskih projavlenij saharnogo diabeta Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2010;4:63-67. (In Russ.).